ThursdayDec 28, 2017 10:16 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Subsidiary Receives Dealer License from Health Canada

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that Health Canada has issued its research and development subsidiary, Cannevert Therapeutics Ltd. (“CTL”), a dealer license allowing it to possess, analyze, sale, send, transport and deliver cannabis, hemp and related products. Per the release, reception of this license marks a “significant step” for CTL as it seeks to discover and develop new therapeutic cannabis strains while also providing commercial chemical and biological testing services for licensed producers under Health Canada guidelines. “We are excited that Cannevert scientists will now not only…

Continue Reading

ThursdayDec 21, 2017 9:55 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Enters LOI for Merger with Tokyo Smoke; Announces Investment from Aphria Inc.

Premium cannabis lifestyle brand DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) this morning announced its entry into a binding letter of intent setting out the terms pursuant to which it proposes to acquire all of the issued and outstanding shares of Tokyo Smoke. Per the update, the proposed merger will create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer and a retail-focused cannabis company. The combined company is expected to operate under the name “Hiku Brands Company Ltd.” in reference to the brand house containing premium cannabis brands DOJA, Tokyo Smoke and Van der Pop. Additionally,…

Continue Reading

MondayDec 18, 2017 12:08 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Added to Horizons Marijuana Life Sciences Index ETF

Horizons ETFs Management (Canada) Inc. recently announced completion of its quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”). Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is one of 11 new holdings that have been added to HMMJ’s portfolio, which is the world’s first ETF offering direct exposure to North American-listed securities involved with marijuana bioengineering and production. “Cannabis has been one of the newest and fastest-growing asset classes of 2017, presently valued at approximately $23 billion,” Steve Hawkins, president and CEO of Horizons ETFs, stated in a news release.…

Continue Reading

FridayDec 15, 2017 9:24 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Launches New Research Programs

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development ("R&D") program; R&D regarding nicotine edibles; and provided an update on existing R&D programs. The company has developed topical cream products for the delivery of cannabinoids as an addition to its DehydraTECH™ technology. Laboratory testing for human skin absorption and penetration characteristics are scheduled for early 2018 for various formulations. Following its recent nicotine patent grant, Lexaria is advancing its research focus on edible forms of nicotine that could utilize the company’s DehydraTECH™ technology. Additionally, Lexaria plans to further…

Continue Reading

WednesdayDec 13, 2017 11:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Granted U.S. Patent Regarding DehydraTECH™ Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO") increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be…

Continue Reading

TuesdayDec 12, 2017 9:29 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Inks LOI to Acquire Outstanding Shares of Harvest Medicine Inc.

Abcann Global (TSX.V: ABCN) (OTCQB: ABCCF) this morning said that the company recently entered into a binding Letter of Intent (“LOI”) dated December 11, 2017 to acquire all outstanding securities of Canada’s fastest growing medical cannabis clinic, Harvest Medicine Inc. Per the terms of the agreement, Abcann will make a $1,500,000 cash payment and issue 1,056,338 common shares in the capital of ABcann valued at $1,500,000, based on a deemed price of $1.42 per share. Upon the closing of the transaction, Harvest Medicine founder and CEO, Shekhar Parmar, is anticipated to join ABcann’s executive team as Chief Strategy Officer and…

Continue Reading

FridayDec 08, 2017 8:31 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Retains Medical Director to Advise Cannabis Research Programs

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director. Alexander’s role will be to confirm the medical integrity of cannabis research programs conducted by the company’s subsidiary, Cannevert Therapeutics Ltd. In addition, Alexander will develop a medical affairs strategy to support cannabis strains currently in development. “Dr. Alexander brings a wealth of medical knowledge, a clear understanding of current clinical practice and regulatory needs, and a pledge to educate all stakeholders about therapeutic strains that are based on Cannevert’s experimental evidence,” Veritas CEO Dr. Lui…

Continue Reading

TuesdayDec 05, 2017 8:29 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. Per the agreement, the Institute for Medical Cannabis will provide CTL with particular cannabis strains for upcoming human studies in the US territory. “We are pleased that Cannevert has identified a reputable producer that is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and conducting clinical research on its products. They will…

Continue Reading

MondayDec 04, 2017 9:04 am

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018. The company’s incoming president and CEO Nick Dean intends to focus on meeting the expected surge in demand in the recreational cannabis sector through strategic partnerships and by increasing Emblem’s total production capacity. Dean also intends to ramp up patient acquisition in the medical cannabis market utilizing the company’s strengths and quality products. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic…

Continue Reading

FridayDec 01, 2017 11:41 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Posts Q3 Results, Operational Update

Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017. Among other highlights from the third quarter, the company reported $43.4 million in cash, cash equivalents and marketable securities which provides a strong position for expansion plans for its high-tech Vanluven facility. Abcann also reported revenues of $614,000 for the nine months ended September 30, 2017, a considerable increase compared to $211,00 during the same period in 2016. Additionally, the company provided an update on operations, including the company’s strategy moving forward. “ABcann’s vision is to create a successful…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977